Published

With great power comes great responsibility: Promise and caution in the new psychedelic renaissance

An abstract is available from the original source but is not redistributed by this tracker. Read the source record.

Open source BibTeX RIS

Bibliographic context

Journal: Brain Disorders
Date: 2025-09-23
Source: OpenAlex
DOI: 10.1016/j.dscb.2025.100286
PubMed: Unavailable

Authors

Matthew Halma R. Levy Joseph Varón

Watch author

Derived topics and classifications

psilocybin Depression Addiction Consciousness Aging Clinical Trial Review Article Treatment-Resistant Depression Healthcare Workers Safety Adverse Events Clinical Trial

Citation graph

0 referenced DOIs found in stored source metadata. 2 indexed papers cite this DOI.

Open citation network

Indexed papers citing this DOI

Past-Year Psilocybin and Alcohol Co-Use: Associations With Mental Health Symptoms2026-07-01 With great power comes great responsibility: Promise and caution in the new psychedelic renaissance2025-09-23

Related papers

Psychedelic Therapy for DepressionUnknown journal · 2026-08-11 Evaluating psilocybin for the management of depression: a literature reviewBritish Journal of Mental Health Nursing · 2026-08-02 Psychedelic Therapies in the Management of Post-Traumatic Stress DisorderJournal of Education Health and Sport · 2026-07-16 A Systematic Review of EEG Predictors and Correlates of Psilocybin’s Treatment in DepressionUndergraduate Research in Natural and Clinical Science and Technology (URNCST) Journal · 2026-07-27 Psilocybin-Assisted Therapy in Psychiatry: A Narrative Clinical Review of Mechanisms, Therapeutic Applications, and Emerging Evidence (2025-2026)Journal of Clinical Medicine · 2026-08-12 Psilocybin-assisted therapy for treatment-resistant major depressive disorder in a public healthcare setting: a randomized controlled trial.Nature medicine · 2026-08-06 Beyond Monoamines: Ketamine, Esketamine, and Classic Psychedelics in the Treatment of DepressionZenodo (CERN European Organization for Nuclear Research) · 2026-07-17 An Open-Label Trial Protocol to Test Menstrual Cycle Effects and Tolerance to Low-Dose Psilocybin in Healthy Menstruating Persons.Pharmacology · 2026-08-10